<DOC>
	<DOCNO>NCT02935530</DOCNO>
	<brief_summary>Venous thromboembolism ( VTE ) important cause post-operative morbidity mortality woman undergo surgery gynecologic malignancy . Although benefit thromboprophylaxis reduction post-operative VTE event surgery gynecologic cancer well document around world , evidence Chinese woman rare . The investigator design prospective randomize study assess benefit pharmacologic prophylaxis patient receive surgical treatment gynecologic malignancy China .</brief_summary>
	<brief_title>Thromboprophylaxis After Surgery Gynecologic Malignancy China</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<criteria>Patients ovarian cancer , cervix cancer endometrial cancer ; Age ≤ 70 year ; female , Chinese woman ; Initial treatment surgery ; Laboratory test : WBC ≥ 4×10 ( 9 ) /L , NEU ≥ 2×10 ( 9 ) /L , PLT ≥ 100×10 ( 9 ) /L , serum bilirubin ≤ 1.5 time upper limit normal , transaminase ≤ 1.5 time upper limit normal , BUN , Cr ≤ normal No prior pharmacologic prophylaxis ; Provide write informed consent . PLT ≤ 75×10 ( 9 ) /L Vascular injury History thrombosis Liver kidney dysfunction Concurrently participate clinical trial Unable unwilling sign informed consent ; Unable unwilling abide protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>